Financial toxicity in early‐phase cancer clinical trial participants

Sienna M. Durbin,Debra Lundquist,Andrea Pelletier,Laura A. Petrillo,Viola Bame,Victoria Turbini,Hope Heldreth,Kaitlyn Lynch,Mary Boulanger,Anh Lam,Casandra McIntyre,Betty R. Ferrell,Rachel Jimenez,Dejan Juric,Ryan D. Nipp
DOI: https://doi.org/10.1002/cncr.35586
IF: 6.9209
2024-10-11
Cancer
Abstract:Background Little is known about financial toxicity in early‐phase clinical trial (EP‐CT) participants. This study sought to describe financial toxicity in EP‐CT participants and assess associations with patient characteristics and patient‐reported outcomes (PROs). Methods Prospectively enrolled EP‐CT participants from were followed from April 2021 through January 2023. Participants completed the Comprehensive Score for Financial Toxicity (<26 = financial toxicity) at time of treatment. Quality of life (QOL), symptoms, coping, and resource concerns were surveyed. Associations of financial toxicity with patient characteristics, PROs, and clinical outcomes were explored. Results Of 261 eligible patients, 197 completed baseline assessments (75.5%, median age = 63.4 years [31.8‐88.6], 57.4% female). Most common cancers were gastrointestinal (33.0%) and breast (20.8%). More than one third (34.0%) of patients reported financial toxicity. Patients with financial toxicity were more likely to be <65 years (70.2% vs 48.5%, p = .004), unemployed (45.5% vs 16.9%, p
oncology
What problem does this paper attempt to address?